What are the Clinical Implications of ABL Kinase in Cancer?
The discovery of the BCR-ABL fusion protein revolutionized the treatment of CML. The development of tyrosine kinase inhibitors (TKIs) such as imatinib, which specifically target the BCR-ABL kinase, has transformed CML from a fatal disease into a manageable chronic condition for many patients. Imatinib and other second- and third-generation TKIs, like dasatinib and nilotinib, have dramatically improved survival rates and quality of life for CML patients.
